title: Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient.
abstract: OBJECTIVE
  Human herpesvirus-8 (HHV-8)-positive, HIV-negative multicentric Castleman's disease is a rare lymphoproliferative disorder with no standardized treatment. Concurrent Kaposi's sarcoma, another HHV-8-related disease, is uncommon in HIV-negative patients. The role of antiviral therapy and rituximab in HIV-negative patients is not well established.
  
  
  METHODS
  We report a case of a 5-year, durable remission of HHV-8-positive, HIV-negative comorbid multicentric Castleman's disease and Kaposi's sarcoma treated with long-term valganciclovir, following initial rituximab and liposomal doxorubicin.
  
  
  CONCLUSIONS
  Currently, there is no defined role for antiviral therapy in the treatment of HIV-negative HHV-8-positive multicentric Castleman's disease and Kaposi's sarcoma. Ganciclovir followed by indefinite, continuous valganciclovir is thought to have contributed significantly to the durable response in this case.
authors: Department of Medical Oncology, Austin Health, Heidelberg, VIC, Australia.
authors: C
authors: C
authors: Murphy
authors: Department of Medical Oncology, Austin Health, Heidelberg, VIC, Australia.
authors: E
authors: E
authors: Hawkes
authors: Department of Medical Oncology, Austin Health, Heidelberg, VIC, Australia.|Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
authors: F
authors: F
authors: Chionh
authors: Department of Medical Oncology, Austin Health, Heidelberg, VIC, Australia.
authors: G
authors: G
authors: Chong
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D005871:Castleman Disease / Q000188:drug therapy* / Q000821:virology; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy; D006566:Herpesviridae Infections / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D000069283:Rituximab / Q000627:therapeutic use*; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000821:virology; D000077562:Valganciclovir
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D000069283:Rituximab; D004317:Doxorubicin; D000077562:Valganciclovir; D015774:Ganciclovir
keywords: Kaposi's sarcoma; human herpesvirus-8; multicentric Castleman's disease; rituximab; valganciclovir